Immune checkpoint inhibitors have substantially improved survival in advanced melanoma but are also associated with immune-related adverse events.Such events can affect any organ, including the central and peripheral nervous systems.Neurological adverse events are rare and often underrecognized.We report the case of a 53-year-old woman with melanoma who developed a severe neurological adverse event after treatment with the PD-1 inhibitor nivolumab.We describe a rare case of nivolumab-associated glial fibrillary acidic protein astrocytopathy and highlight the diagnostic challenges, therapeutic considerations, and importance of early recognition of these potentially severe neurological adverse events.
Daniello et al. (Sun,) studied this question.